RU2008110082A - Производные бензотиадиазолифенилалкиламина для лечения состояний, облегчаемых обратным захватом моноамина - Google Patents
Производные бензотиадиазолифенилалкиламина для лечения состояний, облегчаемых обратным захватом моноамина Download PDFInfo
- Publication number
- RU2008110082A RU2008110082A RU2008110082/04A RU2008110082A RU2008110082A RU 2008110082 A RU2008110082 A RU 2008110082A RU 2008110082/04 A RU2008110082/04 A RU 2008110082/04A RU 2008110082 A RU2008110082 A RU 2008110082A RU 2008110082 A RU2008110082 A RU 2008110082A
- Authority
- RU
- Russia
- Prior art keywords
- compound according
- substituents
- alkyl
- subject
- pain
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract 38
- 125000001424 substituent group Chemical group 0.000 claims abstract 35
- 229910052799 carbon Inorganic materials 0.000 claims abstract 21
- -1 alkyl sulfone Chemical class 0.000 claims abstract 15
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 15
- 125000003118 aryl group Chemical group 0.000 claims abstract 13
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 12
- 150000003839 salts Chemical class 0.000 claims abstract 12
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 9
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 9
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 7
- 125000000304 alkynyl group Chemical group 0.000 claims abstract 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 7
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 7
- 229910052736 halogen Inorganic materials 0.000 claims abstract 7
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 6
- 238000006467 substitution reaction Methods 0.000 claims abstract 6
- 125000004423 acyloxy group Chemical group 0.000 claims abstract 5
- 125000000217 alkyl group Chemical group 0.000 claims abstract 5
- 150000002367 halogens Chemical class 0.000 claims abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 5
- 125000004429 atom Chemical group 0.000 claims abstract 4
- 125000005360 alkyl sulfoxide group Chemical group 0.000 claims abstract 3
- 125000004422 alkyl sulphonamide group Chemical group 0.000 claims abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract 3
- 125000005362 aryl sulfone group Chemical group 0.000 claims abstract 3
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims abstract 3
- 125000006622 cycloheptylmethyl group Chemical group 0.000 claims abstract 3
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims abstract 3
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 3
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 3
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims abstract 2
- 125000005361 aryl sulfoxide group Chemical group 0.000 claims abstract 2
- 125000004104 aryloxy group Chemical group 0.000 claims abstract 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 26
- 208000002193 Pain Diseases 0.000 claims 16
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 208000001640 Fibromyalgia Diseases 0.000 claims 5
- 150000001721 carbon Chemical group 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- 230000001457 vasomotor Effects 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 3
- 208000020401 Depressive disease Diseases 0.000 claims 3
- 201000001880 Sexual dysfunction Diseases 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 230000002496 gastric effect Effects 0.000 claims 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 231100000872 sexual dysfunction Toxicity 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229910005965 SO 2 Inorganic materials 0.000 claims 2
- 206010046543 Urinary incontinence Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- XIOOKHAKCQPDFN-UHFFFAOYSA-N n-methyl-3-(1-methyl-2,2-dioxo-2$l^{6},1,3-benzothiadiazol-3-yl)-3-phenylpropan-1-amine Chemical compound C12=CC=CC=C2N(C)S(=O)(=O)N1C(CCNC)C1=CC=CC=C1 XIOOKHAKCQPDFN-UHFFFAOYSA-N 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 208000009935 visceral pain Diseases 0.000 claims 2
- CXHQHTUZVMWSEW-UNTBIKODSA-N (3r)-3-(2,2-dioxo-1-propan-2-yl-2$l^{6},1,3-benzothiadiazol-3-yl)-3-(3-fluorophenyl)-n-methylpropan-1-amine;hydrochloride Chemical compound Cl.C1([C@H](N2S(N(C(C)C)C3=CC=CC=C32)(=O)=O)CCNC)=CC=CC(F)=C1 CXHQHTUZVMWSEW-UNTBIKODSA-N 0.000 claims 1
- GKJHIXURPAKWNI-QGZVFWFLSA-N (3r)-3-(2,2-dioxo-1-propan-2-yl-2$l^{6},1,3-benzothiadiazol-3-yl)-n-methyl-3-phenylpropan-1-amine Chemical compound C1([C@H](N2S(N(C(C)C)C3=CC=CC=C32)(=O)=O)CCNC)=CC=CC=C1 GKJHIXURPAKWNI-QGZVFWFLSA-N 0.000 claims 1
- XJBASQDXPLMPBC-XFULWGLBSA-N (3r)-3-(3-chloro-5-fluorophenyl)-n-methyl-3-(1-methyl-2,2-dioxo-2$l^{6},1,3-benzothiadiazol-3-yl)propan-1-amine;hydrochloride Chemical compound Cl.C1([C@H](N2S(N(C)C3=CC=CC=C32)(=O)=O)CCNC)=CC(F)=CC(Cl)=C1 XJBASQDXPLMPBC-XFULWGLBSA-N 0.000 claims 1
- KQSXERKQULHTPO-HXUWFJFHSA-N (3r)-3-[1-(4-chlorophenyl)-2,2-dioxo-2$l^{6},1,3-benzothiadiazol-3-yl]-n-methyl-3-phenylpropan-1-amine Chemical compound O=S1(=O)N([C@H](CCNC)C=2C=CC=CC=2)C2=CC=CC=C2N1C1=CC=C(Cl)C=C1 KQSXERKQULHTPO-HXUWFJFHSA-N 0.000 claims 1
- WLGQMKWTHWZOMW-XFULWGLBSA-N (3r)-n-methyl-3-(1-methyl-2,2-dioxo-2$l^{6},1,3-benzothiadiazol-3-yl)-3-phenylpropan-1-amine;hydrochloride Chemical compound Cl.C1([C@H](N2S(N(C)C3=CC=CC=C32)(=O)=O)CCNC)=CC=CC=C1 WLGQMKWTHWZOMW-XFULWGLBSA-N 0.000 claims 1
- WLGQMKWTHWZOMW-RSAXXLAASA-N (3s)-n-methyl-3-(1-methyl-2,2-dioxo-2$l^{6},1,3-benzothiadiazol-3-yl)-3-phenylpropan-1-amine;hydrochloride Chemical compound Cl.C1([C@@H](N2S(N(C)C3=CC=CC=C32)(=O)=O)CCNC)=CC=CC=C1 WLGQMKWTHWZOMW-RSAXXLAASA-N 0.000 claims 1
- NRACQAXLKJANGJ-UHFFFAOYSA-N 3-(2,2-dioxo-1-propan-2-yl-2$l^{6},1,3-benzothiadiazol-3-yl)-3-(3-fluorophenyl)-n-methylpropan-1-amine Chemical compound C12=CC=CC=C2N(C(C)C)S(=O)(=O)N1C(CCNC)C1=CC=CC(F)=C1 NRACQAXLKJANGJ-UHFFFAOYSA-N 0.000 claims 1
- GKJHIXURPAKWNI-UHFFFAOYSA-N 3-(2,2-dioxo-1-propan-2-yl-2$l^{6},1,3-benzothiadiazol-3-yl)-n-methyl-3-phenylpropan-1-amine Chemical compound C12=CC=CC=C2N(C(C)C)S(=O)(=O)N1C(CCNC)C1=CC=CC=C1 GKJHIXURPAKWNI-UHFFFAOYSA-N 0.000 claims 1
- SZOYPVWBNHSVAA-UHFFFAOYSA-N 3-(3-chloro-5-fluorophenyl)-3-(2,2-dioxo-1-propan-2-yl-2$l^{6},1,3-benzothiadiazol-3-yl)-n-methylpropan-1-amine Chemical compound C12=CC=CC=C2N(C(C)C)S(=O)(=O)N1C(CCNC)C1=CC(F)=CC(Cl)=C1 SZOYPVWBNHSVAA-UHFFFAOYSA-N 0.000 claims 1
- RDIRCKUHCUHSEB-UHFFFAOYSA-N 3-(3-chloro-5-fluorophenyl)-n-methyl-3-(1-methyl-2,2-dioxo-2$l^{6},1,3-benzothiadiazol-3-yl)propan-1-amine Chemical compound C12=CC=CC=C2N(C)S(=O)(=O)N1C(CCNC)C1=CC(F)=CC(Cl)=C1 RDIRCKUHCUHSEB-UHFFFAOYSA-N 0.000 claims 1
- KQSXERKQULHTPO-UHFFFAOYSA-N 3-[1-(4-chlorophenyl)-2,2-dioxo-2$l^{6},1,3-benzothiadiazol-3-yl]-n-methyl-3-phenylpropan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)N(S1(=O)=O)C2=CC=CC=C2N1C1=CC=C(Cl)C=C1 KQSXERKQULHTPO-UHFFFAOYSA-N 0.000 claims 1
- 208000002485 Adiposis dolorosa Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000015163 Biliary Tract disease Diseases 0.000 claims 1
- 206010006002 Bone pain Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010064012 Central pain syndrome Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010063057 Cystitis noninfective Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 claims 1
- 208000033830 Hot Flashes Diseases 0.000 claims 1
- 206010060800 Hot flush Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
- 206010029216 Nervousness Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010065016 Post-traumatic pain Diseases 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000025609 Urogenital disease Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 claims 1
- 238000002266 amputation Methods 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000037007 arousal Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 208000012696 congenital leptin deficiency Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000005442 glossopharyngeal neuralgia Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 230000009245 menopause Effects 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 208000001022 morbid obesity Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 235000018343 nutrient deficiency Nutrition 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000000578 peripheral nerve Anatomy 0.000 claims 1
- 230000011514 reflex Effects 0.000 claims 1
- 230000001359 rheumatologic effect Effects 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 230000035946 sexual desire Effects 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000022925 sleep disturbance Diseases 0.000 claims 1
- 208000022170 stress incontinence Diseases 0.000 claims 1
- 238000011477 surgical intervention Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000002889 sympathetic effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000012720 thalamic disease Diseases 0.000 claims 1
- 230000000542 thalamic effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 125000004421 aryl sulphonamide group Chemical group 0.000 abstract 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72169305P | 2005-09-29 | 2005-09-29 | |
| US60/721,693 | 2005-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008110082A true RU2008110082A (ru) | 2009-11-10 |
Family
ID=37684875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008110082/04A RU2008110082A (ru) | 2005-09-29 | 2006-09-27 | Производные бензотиадиазолифенилалкиламина для лечения состояний, облегчаемых обратным захватом моноамина |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7601744B2 (https=) |
| EP (1) | EP1934193A1 (https=) |
| JP (1) | JP2009510095A (https=) |
| KR (1) | KR20080050453A (https=) |
| CN (1) | CN101277941A (https=) |
| AR (1) | AR055660A1 (https=) |
| AU (1) | AU2006297208A1 (https=) |
| BR (1) | BRPI0616462A2 (https=) |
| CA (1) | CA2624096A1 (https=) |
| CR (1) | CR9829A (https=) |
| EC (1) | ECSP088300A (https=) |
| GT (1) | GT200600441A (https=) |
| IL (1) | IL190273A0 (https=) |
| NO (1) | NO20081235L (https=) |
| PE (1) | PE20070544A1 (https=) |
| RU (1) | RU2008110082A (https=) |
| TW (1) | TW200804325A (https=) |
| WO (1) | WO2007041258A1 (https=) |
| ZA (1) | ZA200802774B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2007003590A1 (es) * | 2006-12-12 | 2008-02-29 | Wyeth Corp | Compuestos derivados de aril sulfamida; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en prevencion y tratamiento de sintomas vasomotrices, disfuncion sexual, transtornos gastrointestinales, transt |
| WO2009076502A1 (en) * | 2007-12-12 | 2009-06-18 | Wyeth | Methods for the preparation of hydroxy-substituted aryl sulfamide compounds |
| BRPI0908098A2 (pt) * | 2008-02-19 | 2015-08-18 | Adolor Corp | Beloxepina, composição, métodos para tratar dor em um mamífero, para inibir a recaptação de ne, para antagonizar um receptor de 5ht2 e para tratar um distúrbio em um paciente que é responsivo ao tratamento com um composto nri e com um composto antagonista de 5ht2 |
| US20090233959A1 (en) | 2008-02-19 | 2009-09-17 | Adolor Corporation | Beloxepin and analogs for the treatment of pain |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA200000890A1 (ru) | 1998-03-02 | 2001-02-26 | Эли Лилли Энд Компани | Гидрохлорид флуоксетина для уменьшения "приливов" (приступообразных ощущений жара (при климактерическом синдроме)) |
| EP1587781A1 (en) | 2002-11-05 | 2005-10-26 | Eli Lilly And Company | 3-aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake |
| US7491723B2 (en) | 2003-10-14 | 2009-02-17 | Wyeth | Alkanol and cycloalkanol-amine derivatives and methods of their use |
-
2006
- 2006-09-27 PE PE2006001171A patent/PE20070544A1/es not_active Application Discontinuation
- 2006-09-27 JP JP2008533628A patent/JP2009510095A/ja not_active Withdrawn
- 2006-09-27 CA CA002624096A patent/CA2624096A1/en not_active Abandoned
- 2006-09-27 GT GT200600441A patent/GT200600441A/es unknown
- 2006-09-27 AU AU2006297208A patent/AU2006297208A1/en not_active Abandoned
- 2006-09-27 TW TW095135772A patent/TW200804325A/zh unknown
- 2006-09-27 CN CNA2006800360246A patent/CN101277941A/zh active Pending
- 2006-09-27 BR BRPI0616462-5A patent/BRPI0616462A2/pt not_active IP Right Cessation
- 2006-09-27 US US11/528,792 patent/US7601744B2/en not_active Expired - Fee Related
- 2006-09-27 RU RU2008110082/04A patent/RU2008110082A/ru not_active Application Discontinuation
- 2006-09-27 EP EP06815744A patent/EP1934193A1/en not_active Withdrawn
- 2006-09-27 AR ARP060104235A patent/AR055660A1/es unknown
- 2006-09-27 WO PCT/US2006/037962 patent/WO2007041258A1/en not_active Ceased
- 2006-09-27 KR KR1020087007611A patent/KR20080050453A/ko not_active Withdrawn
-
2008
- 2008-03-10 NO NO20081235A patent/NO20081235L/no unknown
- 2008-03-18 IL IL190273A patent/IL190273A0/en unknown
- 2008-03-20 EC EC2008008300A patent/ECSP088300A/es unknown
- 2008-03-26 CR CR9829A patent/CR9829A/es not_active Application Discontinuation
- 2008-03-28 ZA ZA200802774A patent/ZA200802774B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7601744B2 (en) | 2009-10-13 |
| CR9829A (es) | 2008-04-28 |
| GT200600441A (es) | 2007-09-19 |
| CA2624096A1 (en) | 2007-04-12 |
| AU2006297208A1 (en) | 2007-04-12 |
| EP1934193A1 (en) | 2008-06-25 |
| CN101277941A (zh) | 2008-10-01 |
| TW200804325A (en) | 2008-01-16 |
| AR055660A1 (es) | 2007-08-29 |
| ECSP088300A (es) | 2008-04-28 |
| KR20080050453A (ko) | 2008-06-05 |
| ZA200802774B (en) | 2009-01-28 |
| PE20070544A1 (es) | 2007-07-26 |
| JP2009510095A (ja) | 2009-03-12 |
| BRPI0616462A2 (pt) | 2011-06-21 |
| US20070072918A1 (en) | 2007-03-29 |
| NO20081235L (no) | 2008-06-20 |
| IL190273A0 (en) | 2009-09-22 |
| WO2007041258A1 (en) | 2007-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011137419A (ru) | Обратные агонисты и антагонисты гистамина н3 и способы их применения | |
| SG176628A1 (en) | Aminopyrrolidinone derivatives and uses thereof | |
| RU2009149292A (ru) | Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов | |
| NZ598085A (en) | Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid | |
| RU2019114940A (ru) | Лечение катаплексии | |
| WO2006086705B1 (en) | Substituted bis aryl and heteroaryl compounds as selective 5ht2a antagonists | |
| EA201101089A1 (ru) | Производные оксадиазола в качестве агонистов рецептора s1p1 | |
| JP2007508361A5 (https=) | ||
| JP2009530302A5 (https=) | ||
| RU2014102885A (ru) | Способ лечения поликистозных заболеваний почек с помощью производных церамида | |
| RU2006116887A (ru) | Производные n-[гетероарил(пиперидин-2-ил)метил]бензамида, способ получения указанных соединений и их применение в терапии | |
| JP2015531764A5 (https=) | ||
| RU2011148583A (ru) | Соединения n-фенил(пиперазил или гомопиперазинил)бензолсульфонамида или бензолсульфонилфенил(пиперазина или гомопиперазина), пригодные для лечения заболеваний, которые реагируют на модулирование рецептора 5-нт6 серотонина | |
| PE20081395A1 (es) | Derivados de aril sulfamida y metodos para su uso | |
| JP2020528938A5 (https=) | ||
| RU2008110082A (ru) | Производные бензотиадиазолифенилалкиламина для лечения состояний, облегчаемых обратным захватом моноамина | |
| JP2006525297A5 (https=) | ||
| HRP20190927T1 (hr) | Triciklični spojevi, pripravci koji ih sadrže i njihove uporabe | |
| NO20081037L (no) | Fremgangsmate for oppnaelse av 3,3-difenylpropylaminer | |
| RU2015150120A (ru) | Соединение дикарбоновой кислоты | |
| JP2009528317A5 (https=) | ||
| RU2004139041A (ru) | Применение гетероаренкарбоксамидов в качестве дофамин-d3 лигандов для лечения заболеваний центральной нервной системы | |
| AU2012306122A1 (en) | Scheme for administering N-hydroxy-4-{2-[3-(N.N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}benzamide | |
| RU2014104993A (ru) | Кристаллическая форма натриевой соли 4-трет-бутил-n-{4-хлор-2-(1-окси-пиридин-4-карбонил)-фенил}-бензолсульфонамид | |
| RU2007125658A (ru) | Фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофамина-d2 и ингибирования повторного поглощения серотонина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20100908 |